Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
Status:
Completed
Trial end date:
2018-06-18
Target enrollment:
Participant gender:
Summary
The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice
daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of
the participants received ACCU-D1 while one-third of the participants received vehicle
control.